Letters

Who should be liable for funding recombinant factor VIII?

BMJ 1998; 316 doi: https://doi.org/10.1136/bmj.316.7141.1385a (Published 02 May 1998) Cite this as: BMJ 1998;316:1385
  1. Richard G Richards, Consultant public health physician
  1. North Nottinghamshire Health Authority, Ransom Hall, Rainworth, Mansfield, Nottingham NG21 0ER

    EDITOR—On 26 February the Department of Health announced that, acting on advice from the Committee on the Safety of Medicines, it will inform health authorities of “arrangements to ensure that recombinant factor VIII is made available to those [haemophiliac] children under the age of 16 who are not already receiving it, and to new patients.”1 This policy is a response to the perceived threat from blood products contaminated with the new variant Creutzfeldt-Jakob disease prion. This threat is largely theoretical,1-3 although many …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe